PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of PLX51107 and how well it works
with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic
syndrome. PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving PLX51107 and azacitidine may work better than
azacitidine alone in treating patients with acute myeloid leukemia or myelodysplastic
syndrome.